In Vivo Cell Therapy Market Report Scope & Overview:

The In Vivo Cell Therapy Market was valued at USD 212.40 Million in 2025 and is expected to reach USD 3,734.19 Million by 2035, growing at a CAGR of 33.20% from 2026-2035.

The In Vivo Cell Therapy Market is drawing capital toward programs that reprogram T cells, natural killer cells and stem cells directly inside the patient, bypassing the apheresis, viral transduction and lymphodepletion steps that keep conventional cell therapy manufacturing slow and expensive. Large pharmaceutical companies are acquiring platform originators outright rather than waiting for late-stage data, betting that an off-the-shelf, infusion-ready product can undercut the cost structure of autologous CAR-T therapies already on the market. Lentiviral and lipid nanoparticle delivery systems anchor most competing platforms, while receptor engineering for hematological cancers remains the most advanced application. Investment is concentrating around a small group of companies with validated in vivo delivery chemistry, positioning deal-making as the defining competitive dynamic.

⮞In June 2025, AbbVie agreed to acquire Capstan Therapeutics for up to USD 2.1 Billion, adding an in vivo CAR-T platform to its immunology pipeline. The deal signals that large pharmaceutical buyers are now paying premium valuations for in vivo cell engineering platforms years before any product reaches approval.

U.S. In Vivo Cell Therapy Market Outlook

The U.S. In Vivo Cell Therapy Market was valued at USD 102.00 Million in 2025 and is expected to reach USD 1,727.07 Million by 2035, growing at a CAGR of 32.70% from 2026-2035.

The U.S. In Vivo Cell Therapy Market is the largest national market within North America, anchored by a concentration of platform developers, academic medical centers and venture capital that first commercialized ex vivo CAR-T therapy. Acquirers are paying billion-dollar premiums for companies with validated lentiviral or lipid nanoparticle delivery chemistry, treating platform ownership as a faster route to differentiation than internal discovery programs. Specialized research agencies are co-funding programs that aim to remove apheresis and lymphodepletion from treatment, lowering the capital a developer needs before reaching the clinic. Developers are competing to file investigational applications first, since early clinical data increasingly determines which platform attracts the next acquisition or strategic partnership rather than internal pipeline depth alone.

⮞In August 2025, Gilead Sciences acquired Interius BioTherapeutics for USD 350 Million, gaining an in vivo CAR-T platform already cleared for human testing. The purchase extended Gilead's existing CAR-T franchise into a manufacturing model that does not require removing cells from the patient.

By Therapeutic Cell Type, T Cells Dominates the In Vivo Cell Therapy Market and Myeloid Cells Grows Fastest

T cells hold the largest share because every acquired or partnered platform to date, including Capstan Therapeutics and Interius BioTherapeutics, targets T cell reprogramming first, concentrating capital and clinical data around a single cell type. Acquirers favor T cell programs because validated chimeric antigen receptor designs already exist from the ex vivo CAR-T market, shortening the path from deal signing to an investigational filing. Strategic buyers view a T cell platform as a template that can later be redirected toward other cell types, making early T cell deals a foothold rather than a final destination for competing developers.

Myeloid cells are growing fastest as developers position macrophage and dendritic cell reprogramming as the next competitive frontier once T cell platforms mature. Investors are funding early-stage companies pursuing myeloid targets precisely because fewer competitors occupy that space, offering a cleaner path to platform differentiation than crowded T cell programs. Myeloid cells also carry fewer manufacturing constraints tied to viral transduction efficiency, which lowers the technical risk premium buyers attach to a deal. As large pharmaceutical companies exhaust readily available T cell targets, strategic interest is shifting toward myeloid and stem cell reprogramming to secure differentiated pipeline positions.

⮞In March 2025, AstraZeneca agreed to acquire EsoBiotec for up to USD 1 Billion, adding a lentiviral in vivo CAR-T platform built around T cell and NK cell targeting. The deal extended AstraZeneca's oncology pipeline into in vivo cell engineering without an internal discovery program.

By Therapeutic Application, Hematological Malignancies Dominates the In Vivo Cell Therapy Market and Autoimmune Diseases Grows Fastest

Hematological malignancies account for the largest application share because every approved ex vivo CAR-T therapy already targets blood cancers, giving in vivo developers a proven clinical and regulatory pathway to follow. Acquirers prioritize blood cancer programs because trial design, endpoints and manufacturing comparators are established, reducing the diligence burden before a deal closes. Competing developers can also benchmark their in vivo candidates directly against marketed autologous products, turning cost and convenience into the primary basis for competitive positioning rather than an unproven mechanism, which keeps capital concentrated on blood cancer indications ahead of solid tumor or autoimmune programs.

Autoimmune disease programs are growing fastest as developers reposition receptor-engineered cells to deplete pathogenic B cells rather than tumor cells, a shift that several oncology-focused platforms are now pursuing in parallel. Strategic buyers see autoimmune indications as a way to diversify a single platform across a larger patient population without building a second delivery technology. Clinical signals from ex vivo CAR-T in lupus and related conditions are drawing comparable interest toward in vivo approaches, encouraging companies with validated T cell platforms to open autoimmune disease programs alongside their original oncology focus to broaden commercial reach.

⮞In February 2026, Eli Lilly agreed to acquire Orna Therapeutics for up to USD 2.4 Billion to gain a circular RNA platform capable of programming immune cells against both cancer and autoimmune targets. The acquisition widened the competitive field for in vivo platforms positioned across more than one disease category.

By In Vivo Cell Engineering Technology, Receptor Engineering Dominates the In Vivo Cell Therapy Market and Gene Editing and Gene Modification Grows Fastest

Receptor engineering leads the technology segment because chimeric antigen and T cell receptor constructs are the most clinically advanced mechanism for directing immune cells toward a target, carried over directly from the ex vivo CAR-T market. Acquirers treat a validated receptor engineering platform as the lowest-risk entry point into in vivo cell therapy, since the biology of the receptor itself does not need to be reinvented, only the in vivo delivery method around it. This has made receptor engineering companies the most frequent acquisition targets, with buyers competing on delivery chemistry rather than on the underlying receptor science.

Gene editing and gene modification is growing fastest as companies apply base editing and gene writing tools to correct or install genes directly within circulating or resident immune cells, moving beyond the single function of adding a receptor. Developers pursuing this approach argue it supports a broader set of diseases, including inherited blood disorders, than receptor engineering alone can address. Research funding bodies are backing gene writing platforms specifically for in vivo CAR-T applications, a signal that technology buyers expect gene editing approaches to capture a larger share of future deal value as the underlying science matures.

⮞In January 2024, AbbVie and Umoja Biopharma entered a strategic collaboration worth up to USD 1.4 Billion in potential milestones to advance in situ CAR T cell gene modification programs. The option-based structure let AbbVie secure future access to Umoja's lentiviral platform without committing to a full acquisition at this stage.

By Delivery Modality, Viral Vector-Based Dominates the In Vivo Cell Therapy Market and Lipid Nanoparticle-Based Grows Fastest

Viral vector-based delivery holds the largest share because lentiviral and adeno-associated vectors carry the longest clinical history of any method used to modify cells inside the body, giving regulators and acquirers a familiar safety record to evaluate. Companies built around viral delivery, including early entrants later acquired by large pharmaceutical buyers, established much of the manufacturing and quality infrastructure that newer platforms still depend on. This head start in process knowledge keeps viral vector-based programs ahead in deal volume, even as buyers increasingly ask whether a non-viral alternative could eventually replace the vector entirely.

Lipid nanoparticle-based delivery is growing fastest as developers and government research funders back non-viral programs that avoid the manufacturing complexity and insertional risk associated with viral vectors. A lipid nanoparticle approach can be redosed and manufactured more quickly than a viral vector batch, advantages that are drawing fresh competitive entrants away from established viral platforms. Several companies originally focused on messenger RNA vaccines are repositioning lipid nanoparticle expertise toward in vivo cell engineering, intensifying competition for the specialized formulation talent and intellectual property needed to scale this delivery route across multiple disease programs.

⮞In October 2025, Tessera Therapeutics received up to USD 41.3 Million from ARPA-H's EMBODY program to advance a lipid nanoparticle-delivered in vivo CAR-T therapy. The award specifically targets a single-dose treatment designed to avoid viral vectors, apheresis and lymphodepletion entirely.

Regional Analysis

North America In Vivo Cell Therapy Market Insights

With a share of 54.70% in 2025, North America led the market, anchored by the United States, where nearly every major in vivo cell therapy acquisition and strategic collaboration to date has been negotiated and closed. Concentration of venture capital, academic cell and gene therapy centers, and an established ex vivo CAR-T manufacturing base gives acquirers ready access to platforms, personnel and clinical trial sites in one region. Large pharmaceutical companies headquartered in the United States have led nearly every billion-dollar in vivo platform acquisition, reinforcing the region's position as the primary venue where competitive positioning in this market is decided.

Canada contributes a smaller but steady share through academic cell engineering research and participation in multinational clinical trials run by U.S.-headquartered sponsors. Competition within the region is increasingly a contest between specialized platform originators and large pharmaceutical acquirers racing to secure exclusive access before a rival closes a similar deal. Smaller developers without a clear delivery chemistry advantage face growing pressure to partner early rather than attempt a solo path to approval. This dynamic is expected to keep North America ahead on both deal value and clinical trial activity through 2035, even as competing platforms mature in other regions.

⮞In November 2025, Kelonia Therapeutics entered a strategic collaboration with Johnson & Johnson to advance its lentiviral in vivo CAR-T platform toward multiple myeloma. The partnership, followed closely by a separate acquisition agreement, underscored how quickly competitive interest in validated in vivo platforms can escalate from collaboration to outright purchase.

Asia Pacific In Vivo Cell Therapy Market Insights

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 36.90% from 2026 to 2035, as China, Japan, South Korea and Australia attract capital from both regional biotechnology investors and global pharmaceutical buyers seeking lower-cost platform development. China-based developers are forming licensing and co-development agreements with Western sponsors rather than building commercial-stage programs independently, a structure that lets regional companies monetize early discovery work without bearing the full cost of late-stage trials. Government research funding in several Asia Pacific markets is also prioritizing cell and gene engineering, creating a supportive policy environment.

Pregene Biopharma's licensing arrangement with Gilead's Kite unit illustrates how regional developers are becoming preferred partners for Western companies seeking faster, lower-cost access to in vivo candidates. Lower clinical trial costs, faster patient enrollment and government support for local biotechnology sectors give several Asia Pacific developers a cost advantage over counterparts in North America and Europe. Intellectual property protection and regulatory review timelines still vary widely across the region, which can complicate multi-country trial design. Even so, the combination of deep-pocketed Western acquirers and ambitious local platform originators is expected to keep deal flow and clinical trial activity accelerating fastest in Asia Pacific through 2035.

⮞In October 2025, Pregene Biopharma entered a licensing agreement with Gilead's Kite unit worth up to USD 1.6 Billion for access to its in vivo cell therapy candidates. The agreement came two months after Gilead's acquisition of Interius BioTherapeutics, extending its in vivo portfolio through a second deal structure.

Europe In Vivo Cell Therapy Market Insights

Europe is the second largest region in the market, with Germany, the United Kingdom and France hosting a growing share of in vivo cell therapy clinical trial sites. Regulatory agencies across the region, including Germany's Paul Ehrlich Institute, have approved expansion of early-stage in vivo CAR-T trials originally developed by United States-based sponsors, giving European patients access to candidates before a product reaches the regional market independently. This regulatory openness is attracting sponsors that might otherwise have limited early trial activity to the United States alone, broadening the competitive field of sites and investigators available to platform developers.

Strict data protection and consent requirements for genetically modified cell products raise compliance costs for sponsors running trials across several European countries at once. Reimbursement negotiations for cell and gene therapies in the region have historically taken longer than in the United States, which can delay commercial return even after regulatory approval. At the same time, European research consortia and national health systems are showing early interest in in vivo platforms specifically because they could reduce the specialized manufacturing infrastructure that current ex vivo CAR-T therapies require. These factors position Europe as a steady, if slower, contributor to competitive activity through 2035.

⮞In January 2025, Germany's Paul Ehrlich Institute approved the expansion of Interius BioTherapeutics' INVISE trial to include German sites, allowing in vivo cell engineering of CD7-positive T and NK cells inside patients. The approval marked one of the first European regulatory clearances for an in vivo CAR-T candidate developed outside the region.

MEA & Latin America In Vivo Cell Therapy Market Insights

The Middle East and Africa remains a small but strategically watched market, with Saudi Arabia and the United Arab Emirates funding early cancer treatment infrastructure that could eventually support in vivo cell therapy trials. South Africa offers the region's most developed clinical research base for advanced oncology studies. High cancer mortality relative to survival outcomes in the region underscores significant unmet need, though limited specialized treatment centers and low per-capita healthcare spending currently keep most in vivo cell therapy activity confined to international collaborations and donor-funded pilot programs rather than independent regional sponsor-led trials.

Latin America contributes a modest share, led by Brazil, where academic medical centers participate in multinational oncology trials sponsored by United States and European companies. Argentina, Mexico and Colombia add smaller clinical trial capacity, primarily through site participation rather than platform development. Currency volatility and limited venture funding restrict the formation of locally headquartered in vivo cell therapy companies, leaving regional growth dependent on international sponsors choosing Latin American sites for cost and enrollment speed. Expanding cancer registries and growing public health investment are expected to support a gradual increase in trial activity through 2035.

⮞In February 2024, the World Health Organization reported that the African region recorded about 882,000 new cancer cases and 573,000 deaths in 2022, with average survival near 12%. The scale of unmet need illustrates why global sponsors view the region as a long-term rather than near-term priority for in vivo cell therapy trials.

Market Dynamics

Growth Drivers: Billion-dollar acquisitions and government funding are accelerating platform validation

The strongest driver is the willingness of large pharmaceutical companies to acquire clinical-stage platforms outright rather than wait for Phase 3 data, a pattern repeated across billion-dollar deals for Capstan Therapeutics, Orbital Therapeutics and Orna Therapeutics within roughly eighteen months. These transactions validate in vivo cell engineering as a commercially credible category well before any product reaches approval, pulling additional venture and strategic capital toward earlier-stage companies pursuing similar mechanisms. Competing buyers now monitor clinical-stage in vivo developers closely, aware that waiting for more mature data risks losing access to a platform to a rival acquirer.

A second driver is direct government research funding that targets the specific technical barriers slowing in vivo platforms, including delivery efficiency and manufacturing simplification. Specialized federal research programs are co-funding in vivo CAR-T development explicitly to remove apheresis, viral vector risk and lymphodepletion from treatment, effectively subsidizing technical risk that would otherwise fall entirely on private investors. This funding lowers the capital a developer needs before its platform attracts acquirer attention, widening the pool of companies that can credibly compete for a strategic deal. Together, acquisition activity and public funding are compounding to pull the category forward faster than clinical data alone would support.

⮞In May 2025, Ensoma announced that the U.S. Food and Drug Administration cleared its investigational new drug application for EN-374, which the company describes as the first in vivo hematopoietic stem cell-directed gene insertion therapy to reach human testing. The clearance extended in vivo cell engineering beyond CAR-T into stem cell-based approaches for inherited disease.

Restraints: Regulatory scrutiny and unresolved manufacturing risk are slowing platform commercialization

Regulators are applying the lessons of ex vivo CAR-T safety monitoring to in vivo candidates before most have entered large trials, raising the evidentiary bar new entrants must clear. A class-wide boxed warning tied to secondary T cell malignancy risk already covers approved ex vivo CAR-T products, and in vivo developers expect comparable scrutiny once their own candidates reach meaningful patient numbers. This anticipated oversight is lengthening the diligence period acquirers apply before closing a deal, since a safety signal discovered after a transaction closes can erase much of the value a buyer intended to capture.

Manufacturing risk also persists because in vivo delivery still depends on reaching the intended cell type precisely enough to avoid off-target effects in healthy tissue, a problem that remains only partially solved across both viral vector and lipid nanoparticle platforms. Smaller developers without proprietary delivery chemistry struggle to differentiate their programs, limiting them to partnership rather than independent commercialization. Trial design uncertainty, since regulators have not yet settled on standard endpoints for in vivo products, adds further cost and timeline risk. These combined pressures are consolidating competitive activity around a small number of well-funded, acquisition-ready platforms rather than a broad field of independent challengers.

⮞In January 2024, the U.S. Food and Drug Administration requested class-wide boxed warning language for approved CAR-T cell therapies addressing the risk of secondary T cell malignancy. The request applies to ex vivo products already on the market, but it sets a regulatory precedent that in vivo developers expect to face as their own candidates advance.

Opportunities: Disease expansion and strategic repositioning are opening new competitive openings

The clearest opportunity lies in extending validated platforms beyond their original cancer indication into autoimmune disease and inherited blood disorders, broadening the addressable patient population a single delivery technology can serve. Companies that built their initial pipeline around oncology are now opening parallel programs in other disease areas specifically to justify the valuations acquirers are already paying for platform access. This repositioning lets a developer compete on breadth of application rather than only on speed to a single approval, a strategy that is reshaping how acquirers compare competing platforms during diligence.

A second opportunity comes from companies originally focused on messenger RNA vaccines or gene writing redirecting their delivery expertise toward in vivo cell engineering, a pivot that several organizations confirmed publicly within the past year. This cross-industry movement is expanding the competitive field beyond the original group of dedicated cell therapy developers, adding well-capitalized entrants with existing lipid nanoparticle manufacturing experience. Partnerships between regional developers in Asia Pacific and Western pharmaceutical companies are also opening a lower-cost path to clinical data, giving smaller companies a credible route to a strategic deal even without the balance sheet to run a global trial independently.

⮞In November 2025, Sana Biotechnology reported third-quarter results confirming an increased focus on in vivo CAR-T programs alongside its type 1 diabetes pipeline. The shift illustrates how companies with broader cell engineering platforms are reallocating resources toward in vivo approaches as competitive and investor interest in the category has grown.

In Vivo Cell Therapy Market Key Players

• Gilead Sciences, Inc.

• Legend Biotech Corporation

• Eli Lilly and Company

• AbbVie Inc.

• AstraZeneca plc

• Bristol Myers Squibb Company

• CRISPR Therapeutics AG

• Umoja Biopharma, Inc.

• Ensoma, Inc.

• Tessera Therapeutics, Inc.

• Sana Biotechnology, Inc.

• Pregene Biopharma Co., Ltd.

• CREATE Medicines, Inc.

In Vivo Cell Therapy Market Report Scope: